Quarterly report pursuant to Section 13 or 15(d)

Shareholders' Equity (Details)

v3.10.0.1
Shareholders' Equity (Details) - USD ($)
9 Months Ended
Aug. 03, 2017
Sep. 30, 2018
Sep. 30, 2017
Sep. 30, 2016
Shareholders' Equity (Textual)        
Stock based compensation   $ 1,647,444 $ 4,829,598  
Gross proceeds from equity $ 7,000,000      
Stock Award Agreements [Member]        
Shareholders' Equity (Textual)        
Stock based compensation   944,300    
2015 Equity Plan [Member]        
Shareholders' Equity (Textual)        
Aggregate shares of restricted common stock       1,349,000
Shares vest upon consummation of equity and/or debt financing       $ 5,000,000
SAB Amendments [Member]        
Shareholders' Equity (Textual)        
Recognized total expense   $ 22,500    
Restricted common stock, description The SAB Amendments extend the term of the agreements from May 1, 2017 until April 30, 2018 and provide for the following equity based compensation: (a) for Dr. Frost, a warrant to purchase 2,000,000 shares of the Company's Common Stock (the "Frost Warrant") and an award of 150,000 shares of the Company's unregistered restricted Common Stock and (b) for Mr. Rubin, an award of 100,000 shares of the Company's unregistered restricted Common Stock. The restricted stock vests upon the occurrence of a change of control (as defined in the SAB Amendments).      
Warrant term 5 years      
Warrant exercise price $ 1.00